The relative contribution of the CYP2C19*2 polymorphism in the low responsiveness to clopidogrel in the VASP-02 study

被引：0
|
作者：
Aleil, B. [1 ]
De Poli, F. [2 ]
Zaehringer, M. [1 ]
Collet, J. P. [3 ,4 ]
Montalescot, G. [3 ,4 ]
Leon, C. [5 ]
Cazenave, J. P. [5 ]
Dickele, M. C. [2 ]
Monassier, J. P. [6 ]
Gachet, C. [5 ]
机构：
[1] Clin Orangerie, Strasbourg, France
[2] Ctr Hosp Gen, Serv Cardiol, Haguenau, France
[3] Hop La Pitie Salpetriere, AP HP, Inst Cardiol, Paris, France
[4] Hop La Pitie Salpetriere, AP HP, INSERM, U856, Paris, France
[5] Univ Strasbourg, INSERM, UMR S 949, Etab Francais Sang Alsace, Strasbourg, France
[6] Hop Emile Muller, Serv Cardiol, Mulhouse, France
来源：
EUROPEAN HEART JOURNAL | 2009年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：327 / 328
页数：2
相关论文
共 50 条
  • [11] The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19☆2 genotyping
    Langaee, Taimour Y.
    Zhu, Hao-Jie
    Wang, Xinwen
    El Rouby, Nihal
    Markowitz, John S.
    Goldstein, Joyce A.
    Johnson, Julie A.
    PHARMACOGENETICS AND GENOMICS, 2014, 24 (08): : 381 - 386
  • [12] CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention
    Mejin, Melissa
    Tiong, Wen Ni
    Lai, Lana Yin Hui
    Tiong, Lee Len
    Bujang, Adam Mohamad
    Hwang, Siaw San
    Ong, Tiong Kiam
    Fong, Alan Yean Yip
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (04) : 621 - 628
  • [13] CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention
    Melissa Mejin
    Wen Ni Tiong
    Lana Yin Hui Lai
    Lee Len Tiong
    Adam Mohamad Bujang
    Siaw San Hwang
    Tiong Kiam Ong
    Alan Yean Yip Fong
    International Journal of Clinical Pharmacy, 2013, 35 : 621 - 628
  • [14] The clinical impact of CYP2C19 *2 and *3 polymorphism on Clopidogrel and cost analysis
    Al Meman A
    Khalaf H
    Rasool Seemab
    BMC Genomics, 15 (Suppl 2)
  • [15] Example of the Contribution of Pharmacogenetics to Pharmacovigilance in Morocco: Prevalence of the CYP2C19*2 Polymorphism and Clopidogrel Resistance in Moroccan Population
    Lamzouri, A.
    El Rherbi, A.
    Sefiani, H.
    Benabdallah, G.
    Tebaa, A.
    Soulaymani Bencheikh, R.
    Sefiani, A.
    DRUG SAFETY, 2019, 42 (10) : 1267 - 1267
  • [16] Clopidogrel, CYP2C19, and a Black Box
    Ford, Neville F.
    Taubert, Dirk
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03): : 241 - 248
  • [17] The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance
    Kim, K. A.
    Park, P. W.
    Hong, S. J.
    Park, J-Y
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (02) : 236 - 242
  • [18] CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients
    Yang Jie
    Zhao Hong-Dong
    Tan Jie
    Ding Yun-Long
    Zou Jian-Jun
    PHARMAZIE, 2013, 68 (03): : 183 - 186
  • [19] Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite
    Boulenc, Xavier
    Djebli, Nassim
    Shi, Juan
    Perrin, Laurent
    Brian, William
    Van Horn, Robert
    Hurbin, Fabrice
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (01) : 187 - 197
  • [20] The CYP2C19 enzyme polymorphism
    Wedlund, PJ
    PHARMACOLOGY, 2000, 61 (03) : 174 - 183
12345